Lung cancer breakthrough: drug combination cuts death risk by 58% in major trial

ynet (אנגלית) תרבות

A Phase 3 trial involving 563 patients found that combining tarlatamab with immunotherapy extended median survival from 12.7 to 21.1 months; researchers hailed the results at a Madrid oncology conference, although serious side effects and…